Construction of a new facility to be built in Leduc is expected to be completed in nine to 12 months

By Emilie Charette
Reporter
Troy Media

One of Calgary’s neighbours to the north, Leduc, will soon be home to a 25,000 SQF research and manufacturing facility for Polar Bear Genome (PBG) BioPharma Canada Corporation, a biopharmaceutical company.

Dr. Jacqueline Shan, president, CEO, and chief science officer of PBG BioPharma
Dr. Jacqueline Shan
President, CEO, and chief science officer of PBG BioPharma

“We are very excited to have made the first step towards building a fully licenced GMP manufacturing and laboratory facility that will not only function as a research and manufacturing centre for our company, but as a resource for other industries looking to manufacture and develop their own products,” said Dr. Jacqueline Shan, president, CEO, and chief science officer of PBG BioPharma in a news release.

Although the ribbon-cutting event will be held on August 8 and the offices will open for work, construction of the facility is expected to be completed in nine to 12 months. Upon completion, the facility is expected to create 50 new jobs over a three-year period.

According to its website, the company aims to “bring Canadians the absolute best in natural health by delivering trustworthy, transparent, and traceable products.”

This is done using proprietary GenBioChem Triple Fingerprinting Technology, which analyzes chemical profiles of extracts, tests products for their biological effects, and gauges products’ efficacy on humans.

Their products are “vigorously tested and standardized by chemical, biological, and genomic fingerprinting to ensure consistent purity, potency, and targeted efficacy batch to batch and are in compliance with regulatory and industry standards,” according to a news release.

Founded in Edmonton in 2018 and based in Alberta and Ontario, PBG BioPharma operates with an emphasis on Canada-based medicinal herbs and medical cannabis in its products.

Currently, the company is carrying out research, development, and clinical testing in both Alzheimer’s and pain management.

Besides housing and performing PBG BioPharma’s own work, the new facility will offer contracts to Canadian and international businesses for product development and manufacturing services with a “suite of chemical analysis, biological, pharmacological, and quality testing labs,” according to their website.

Emilie Charette is a graduate of the Southern Alberta Institute of Technology’s journalism program and a member of Troy Media’s student internship program. She is also the former editor of the Emery Weal, which is published weekly by SAIT. 

For more information on Troy Media’s internship program, contact our publisher.

© Troy Media


PBG Biopharma

The views, opinions and positions expressed by columnists and contributors are the author’s alone. They do not inherently or expressly reflect the views, opinions and/or positions of our publication.

You must be logged in to post a comment Login